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In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In May 2017, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]
piperidine-4-carboxylate, commonly known as carfentanil, 
through a joint assessment based upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on carfentanil satisfied criteria 1, 4, 5, and 6. The 
two agencies therefore concluded that sufficient information 
had been accumulated to merit the production of a Joint 
Report on carfentanil as stipulated by Article 5.1 of the 
Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
18 May 2017 the EMCDDA and Europol launched a procedure 
for the collection of information on carfentanil, in order to 
prepare the Joint Report. The information was collected 
mainly through the Reitox national focal points in the Member 
States and Norway as well as the Europol national units. In 
addition, the EMA collected information through the national 
competent authorities responsible for human and veterinary 
medicinal products in the Member States as well as in Norway, 
Iceland and Liechtenstein. The EMA also provided information 
as relevant to the centralised procedure for authorising 
medicinal products. The information collection process was 
largely concluded by 29 June 2017.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol national units to provide 
information on:
 ¡ the level of production of carfentanil in their country;
 ¡ the level of distribution of carfentanil in their country;
 ¡ the level of trafficking of carfentanil in their country, both 
for internal, transit or export purposes;
 ¡ the number of seizures of carfentanil in their country, the 
total amount of the seizures, country of origin, details on 
the physical forms (including photos);
 ¡ the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of carfentanil in 
their country; and,
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of carfentanil.
Europol received responses from 18 Member States (2) and 
Canada.
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the 
Member States, Norway, Iceland, and Liechtenstein, provide 
information on whether:
 ¡ the new psychoactive substance carfentanil has obtained a 
marketing authorisation;
 ¡ the new psychoactive substance carfentanil is the subject 
of an application for a marketing authorisation; and,
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance carfentanil has been 
suspended.
Twenty-one countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant 
to the centralised procedure for authorising human and 
veterinary medicinal products.
Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
(2) In alphabetical order: Austria, Belgium, Cyprus, Czech Republic, Finland, 
France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Poland, 
Romania, Slovakia, Slovenia, Sweden, and the United Kingdom.
(3) Austria, Belgium, Estonia, Finland, Germany, Greece, Ireland, Latvia, the 
Netherlands, Slovenia, Spain, and Sweden provided a response in relation to 
human and veterinary medicinal products. Croatia, Czech Republic, Hungary, and 
the United Kingdom provided a response in relation to human medicinal 
products. France, Italy, Poland, Portugal, and Slovakia provided a response in 
relation to veterinary medicinal products.
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products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
carfentanil is used to manufacture a medicinal product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation; and,
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-one countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from 28 Member 
States and Norway (5);
 ¡ reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not carfentanil is under 
assessment by the United Nations system; and,
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’), and, online vendors 
selling carfentanil.
Thus, the information included in sections 3.2.1 and 3.3 of 
the Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information included 
in sections 3.8.3 (in part) and 4 was provided by the EMA.
(4) Austria, Belgium, Estonia, Finland, Germany, Greece, Ireland, Latvia, the 
Netherlands, Slovenia, Spain, and Sweden provided a response in relation to 
human and veterinary medicinal products. Croatia, Czech Republic, Hungary, and 
the United Kingdom provided a response in relation to human medicinal 
products. France, Italy, Poland, Portugal, and Slovakia provided a response in 
relation to veterinary medicinal products.
(5) A reply was not received from Turkey. 
l  3. Information required by Article 5.2 of the Council Decision)
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
l
  3.1 Chemical and physical description, including 
the names under which the new psychoactive 
substance is known (Article 5.2(a) 
of the Council Decision)
Chemical description and names
Carfentanil (6) belongs to the 4-anilidopiperidine class of 
synthetic opioids. This class also includes fentanyl (7), which is 
internationally controlled, and a number of other fentanils (8).
A total of 15 fentanils are controlled under the United Nations 
Single Convention on Narcotic Drugs, 1961, as amended by 
the 1972 Protocol (9).
Carfentanil differs from fentanyl due to the presence of a 
methyl acetate attached at the 4-position of the piperidine 
moiety.
The molecular structure, molecular formula, and molecular 
mass of carfentanil are provided in in Figure 1.
Carfentanil, which is also known as 4-carbomethoxyfentanyl, 
has two positional isomers, 2- and 3-carbomethoxyfentanyl (10). 
The positional isomers of carfentanil differ in the position of 
the methyl acetate on the piperidine ring. The synthesis and 
characterisation of 3-carbomethoxyfentanyl is reported in the 
literature (Mićović et al., 1998).
The synthesis of carfentanil was described in the 1970s 
(Van Daele et al., 1976).
(6) Also known as carfentanyl.
(7) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide. 
(8) In this report, the term ‘fentanils’ is used to describe fentanyl and other 
substances structurally related to fentanyl. 
(9) 3-Methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-methylfentanyl, 
alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxy-3-methylfentanyl, 
beta-hydroxyfentanyl, para-fluorofentanyl, thiofentanyl, acetylfentanyl and 
butyrfentanyl are controlled under Schedule I and IV; alfentanil, fentanyl, 
sufentanil and remifentanil are controlled under Schedule I.
(10) Note that although ‘carfentanil’ can refer to 2-,3-, and 
4-carbomethoxyfentanyl, in this report it will reference the 4-isomer.
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Commonly used names: 
carfentanil or carfentanyl
Systematic (IUPAC) name: 
methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]
piperidine-4-carboxylate
Other chemical names: 
methyl 1-(2-phenylethyl)-4-(N-propanoylanilino)
piperidine-4-carboxylate; 
methyl 1-(2-phenylethyl)-4-[phenyl(propionyl)amino]-
4-piperidinecarboxylate; 
methyl 1-(2-phenylethyl)-4-[phenyl(propionyl)amino]
piperidine-4-carboxylate; 
methyl 1-phenethyl-4-(N-phenylpropionamido)piperidine-
4-carboxylate; 
methyl 1-phenylethyl-4-(N-phenylpropionamido)isonipecotate;
methyl 4-[phenyl(propanoyl)amino]-1-(2-phenylethyl)
piperidine-4-carboxylate; 
methyl 4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-
4-piperidinecarboxylate;
1-phenethyl-4-(N-propionyl-anilino)-piperidine-4-carboxylic 
acid methyl ester; 
4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-
4-piperidinecarboxylic acid methyl ester;
4-methoxycarbonylfentanyl;
4-carbomethoxyfentanyl;
3-demethyllofentanil
International Nonproprietary Names (INN): 
Carfentanilum (Latin) (11) 
Carfentanil (English) (12)
Other names and code names: 
Carfentanila (Spanish); R33799; NIH 10570; R 31 833; 
R31833
Proprietary names: 
Wildnil (13)
Street names: 
‘C.50’ (14)
Chemical Abstracts Service (CAS) registry numbers (15,16): 
59708-52-0 free base 
61086-44-0 oxalate salt 
61380-27-6 citrate salt
IUPAC International Chemical Identifier Key (InCHI Key) (17): 
YDSDEBIZUNNPOB-UHFFFAOYSA-N
(11) http://www.who.int/medicines/publications/druginformation/innlists/
RL18.pdf?ua=1
(12) http://www.who.int/medicines/publications/druginformation/innlists/
RL18.pdf?ua=1
(13) Wildnil® is the proprietary name for carfentanil citrate marketed by Wildlife 
Laboratories, Incorporated. https://www.fda.gov/downloads/AnimalVeterinary/
Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM473748.pdf
(14) A collected sample reported by Norway, where carfentanil was detected in a 
zip-lock bag containing powder, was labelled ‘C.50’. 
(15) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
(16) CAS RN 60645-15-0 is no longer in use by CAS for carfentanil although some 
vendors still reference this number.
(17) InChI Key is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources.
FIGURE 1 
Molecular structure, molecular formula, and molecular mass of carfentanil. Information on fentanyl is provided for comparison.
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The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the CAS 
registry numbers listed above. The searches returned no hits.
Physical description
Carfentanil contains one basic nitrogen atom in the piperidine 
ring which can readily form salts with organic or inorganic acids.
Carfentanil is available as analytical reference material, 
reported as a pale yellow solid and which is soluble in 
chloroform (CHCl
3
), dichloromethane (DCM) and ethyl acetate 
(18). Due to its similarity to fentanyl, the free base is expected 
to be sparingly soluble in water. The hydrochloride and citrate 
salts are expected to have greater aqueous solubility.
The measured melting point for carfentanil oxalate salt is 
189.5°C (Van Daele et al., 1976) and 152.2°C for the citrate 
salt (Janssen and Van Daele, 1979).
Carfentanil is lipophilic.
Carfentanil has been seized in powder form and as a liquid. A 
more detailed description of seizures and collected samples 
can be found in section 3.2.1 and section 3.2.2.
Detection and analysis
Methods documented in the literature for the detection of 
carfentanil include: gas chromatography – mass spectrometry 
(GC-MS), Fourier transform infrared spectroscopy – 
attenuated total reflectance (FTIR-ATR) (Casale et al., 2017), 
nuclear magnetic resonance (NMR) (Casale et al., 2017, 
Malaquin et al., 2010) and by capillary eclectrophoresis 
coupled to electrospray ionisation tandem mass spectrometry 
(CE-ESI-MSn, n=2,3), specifically non-aqueous capillary 
electrophoresis (NACE)-ESI-MSn (Rittgen et al., 2012).
Methods have also been documented in the literature for the 
detection of carfentanil in biological samples, which include: 
high performance liquid chromatography – atmospheric-
pressure ionisation – tandem mass spectrometry (HPLC-API-
MS-MS) (Wang and Bernert, 2006), solid phase extraction 
(SPE) coupled with liquid chromatography – tandem mass 
spectrometry (LC-MS-MS) (Riches et al., 2012; Shaner et al., 
2014) and ultra-high performance liquid chromatography ion 
trap mass spectrometry with MSn capabilities (UHPLC-Ion 
Trap-MSn) (Shoff et al., 2017).
The use of gas chromatography – flame ionisation detection 
(GC-FID) has been described for the quantitation of 
carfentanil in three illicit samples in the United States 
(18) https://www.trc-canada.com/prod-img/MSDS/C183480MSDS.pdf
(Casale et al., 2017). The samples were found to contain 
0.62 %, 1.87 % and 0.31 % of carfentanil hydrochloride. 
Other substances detected in the samples, in trace amounts, 
included: diphenhydramine, fentanyl 2-furanylfentanyl and 
acetylcarfentanil. Carfentanil and acetylcarfentanil gave the 
same GC-MS retention time, however their mass spectra were 
different. The authors also reported that carfentanil citrate 
was easily differentiated from carfentanil hydrochloride when 
using NMR.
The implementation of chromatographic techniques, infrared 
and NMR spectrometry allow unambiguous differentiation 
between carfentanil and its two positional isomers, 2- and 
3-carbomethoxyfentanyl. As of July 2017, detection of the 
positional isomers of carfentanil in Europe has not been 
reported to the EMCDDA.
Immunoassays developed for fentanyl are not necessarily 
expected to show cross-reactivity toward carfentanil (Mao 
et al., 2006). Commercially available immunoassays for 
carfentanil typically show cross-reactivity with sufentanil, 
alfenantil and remifentanyl but not with fentanyl (Ujváry, 
2013).
l
  3.2 Information on the frequency, circumstances and/
or quantities in which a new psychoactive substance 
is encountered, and information on the means 
and methods of manufacture of the new psychoactive 
substance (Article 5.2(b) of the Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 18 Member States (Austria, 
Belgium, Cyprus, Czech Republic, Finland, France, Germany, 
Greece, Hungary, Italy, Lithuania, Luxembourg, Poland, 
Romania, Slovakia, Slovenia, Sweden, and the United 
Kingdom) (19).
Five countries provided information on carfentanil (Finland, 
Germany, Lithuania, Sweden and the United Kingdom).
(19) Canada also provided information to Europol on carfentanil.
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The level of production
No information was received in relation to the production of 
carfentanil (20).
The United Kingdom reported that there are indications that 
carfentanil has been shipped from predominantly China/Hong 
Kong and this has either been used as received, or mixed with 
other drugs, for example heroin, or cutting agents before being 
used or sold.
The level of distribution
At least 82 seizures were reported by five Member States: 
Finland (2), Germany (2), Lithuania (64), Sweden (4) and the 
United Kingdom (10) (21).
Finland reported 2 seizures of carfentanil, where the amounts 
were stated as minimal.
Germany reported 1 seizure of 99.3 g in 2016 by German 
customs and a seizure by Canadian law enforcement of 
approximately 62 g of ‘suspected carfentanil’ in June 2017. It 
was found in a package which was en-route from Hong Kong 
to Canada via Germany, using DHL. The seizure took place in 
Vancouver.
In 2017, Lithuania reported 25 seizures of carfentanil 
amounting to 264.777 g and 39 seizures of carfentanil 
amounting to 33.8 g which also contained heroin. The country 
of origin of the carfentanil in the seizures was unknown. 
Lithuania reported that seizures of carfentanil have increased 
in recent years. Carfentanil is often mixed with heroin and 
prepared for heroin users. Most cases are related to heroin 
distribution in the local Roma community.
Sweden reported 4 seizures of carfentanil made by the 
Swedish Police between the end of March and the end of 
April 2017. The amounts seized were reported as very small 
and that they were intended for end users. Two of the seizures 
were linked and were associated with cases that were 
suspected to involve deaths. In one case, it is known that the 
carfentanil was delivered in an envelope. They also stated that 
(20) Canada reported that there is no evidence to date to indicate carfentanil 
production in the country. Carfentanil is sold as counterfeit oxycodone (CDN 80) 
or Xanax tablets. Carfentanil is imported in powder form and then tableted in 
the country.
(21) Canada reported a total of 19 seizures, 10 of which occurred in 2016 and 9 in 
2017. Seizures in 2016 amounted to 2.3 kg of powder and 6 pills. Six of the 
seizures were reported as importations seized at the Vancouver and at the 
Montreal international mail centres. The country of origin was reported as China 
(5 seizures) and Hong Kong (1). Seizures in 2017 occurred between January and 
mid-April and amounted to 258 g of powder (5 seizures) and 22 pills (1). 
The 5 seizures of powders were seized at the border (Vancouver international 
mail centre and FedEx in Memphis). The country of origin was reported as China 
(3 seizures), Hong Kong (1) and the United States (1). Canada also reported that 
powder fentanyl is often mixed with other illicit drugs such as heroin and cocaine. 
At street level, carfentanil is mostly found in tablet form. They noted that, in 2016, 
over 1 kg of carfentanil in powder form was seized imported into Quebec and an 
additional 1 kg was seized in Alberta.
carfentanil is ordered online from international (European) 
vendors and that there are no indications of domestic sale of 
the substance in Sweden.
The United Kingdom reported no seizures from January 
2016 to March 2017. In April and May 2017, 10 seizures of 
carfentanil were seized that amounted to approximately 
100 g. The biggest seizure was reported by Cleveland 
Police: 3 packages were seized amounting to 82 g and 
containing carfentanil, heroin, caffeine and paracetamol. 
Other substances detected in the seizures were: fentanyl (2); 
fentanyl, caffeine, and paracetamol (1); cocaine, caffeine, 
levamisole, phenacetin (1); and caffeine and paracetamol (2).
The National Crime Agency reported that they identified a 
supplier of carfentanil who was using the darknet to advertise 
and distribute carfentanil across the country and also 
internationally. A total of 19 customers in the United Kingdom 
are known to have purchased carfentanil from this site, 
placing a total of 37 orders. The size of orders varied from 50 
mg (15 orders) to 1 g (1 order). It was also reported that there 
have been deaths associated with carfentanil, fentanyl, and 
fentanyl analogues since December 2016.
The level of trafficking
Information related to trafficking routes is limited to the 
seizures reported above. In cases where the country of 
origin was known, China and specifically Hong Kong were 
primarily reported with the United Kingdom and Germany also 
mentioned, but to a lesser extent (22).
Lithuania reported that there are indications that carfentanil 
may be imported from Russia and China.
Information from ongoing investigations in Sweden indicates 
that carfentanil has been bought from internet vendors and 
delivered directly to the user (and/or to relatives of the user) 
from China, the United Kingdom and Germany. There are no 
indications that carfentanil is sold in Sweden.
Information from the United Kingdom indicates that 
carfentanil has been shipped from China/Hong Kong and 
the substance is either used as received, or mixed with other 
drugs, for example heroin, or cutting agents before being used 
or sold on.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from the 28 Member States 
and Norway (5). Of these, 8 Member States and Norway 
(22) Canada reported that carfentanil is imported in powder form and then 
tableted in the country. 
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reported detections of carfentanil (23). Estonia, Germany, 
Finland, Latvia, Lithuania, Sweden and the United Kingdom 
reported seizures of carfentanil. In addition, Belgium, the 
United Kingdom and Norway reported collected samples.
It is important to note that detections of carfentanil may be 
under-reported since the substance is not routinely screened 
for. Three Member States (Belgium, Lithuania and Sweden) 
reported that carfentanil is part of routine screening in some 
(but not all) laboratories.
Since 2016, there has been an increase in detections of 
carfentanil in Europe. The substance was initially detected in 
Latvia and Lithuania between 2012 and 2015. Subsequently, 
it then appeared in Estonia and Finland, and in the last 
18 months or so it has been detected in a further five 
countries for the first time.
Seizures
In total, 755 seizures of carfentanil were reported to the 
EMCDDA by seven Member States: Estonia (116 cases), 
Germany (3), Finland (2), Latvia (387), Lithuania (233), 
Sweden (4) and the United Kingdom (10). The most recent 
reported detections were made in June this year, and at least 
163 seizures reported for the first 6 months in 2017.
A large majority of the seizures were made by the police, with 
additional seizures taking place in custodial settings. Only 
one customs seizure was reported relating to 100 g seized at 
Cologne/Bonn airport in Germany.
Two Member States (Latvia and Lithuania) reported seizures 
from 2012 to 2015, as follows: 1 seizure in 2012 (Latvia), 27 
seizures in 2013 (Latvia and Lithuania), 48 in 2014 (Latvia), 
and 160 in 2015 (Latvia and Lithuania). Latvia, Lithuania, 
Estonia and Finland reported 345 seizures in 2016 and 
Estonia, Germany, Finland, Latvia, Lithuania, Sweden and the 
United Kingdom reported 174 seizures in 2017.
The largest single seizure of carfentanil was reported by the 
United Kingdom. The seizure was made by West Yorkshire 
Police in May 2017, and amounted to 440 g of unadulterated 
carfentanil in powder form. In addition to this seizure, a total of 
six single seizures over 100 g were reported by four Member 
States as follows: Estonia (209.8 g, seized in April 2017), 
Germany (100 g reported through Police correspondence in 
2017), Lithuania (2 seizures of 200 and 138.5 g, reported in 
(23) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
2016 and 2017) and the United Kingdom (2 seizures of 209 
and 150 g).
Powders
Carfentanil was detected in powder form in a total of 
618 cases: Estonia (110 cases), Germany (2), Finland (2), 
Latvia (383), Lithuania (108), Sweden (3) and the United 
Kingdom (10), amounting to nearly 2.7 kg of seized material. 
The quantification of carfentanil is not routinely performed; 
however, data on purity for 44 samples was reported by 
Lithuania.
In 187 of these seizures, carfentanil was the only substance 
reported.
In 278 seizures, carfentanil was detected in mixture with heroin. 
In addition to heroin, other substances detected were: cocaine, 
caffeine, paracetamol, levamisole and phenacetin (4 cases), 
methadone (3 cases), acryloylfentanyl (3), alpha-PHP (2) and 
caffeine and paracetamol (1).
In addition to the above substances, carfentanil has also 
been detected in mixtures with a number of other opioids. 
These include: fentanyl (81 cases), methadone (13), fentanyl 
and furanylfentanyl (10), fentanyl and acryloylfentanyl (7), 
furanylfentanyl (4), tramadol (3) and acryloylfentanyl (2).
Twelve seizures were reported of carfentanil mixed with the 
synthetic cathinone alpha-PHP.
Where reported, the powders were typically ‘yellowish’, both 
in cases where carfentanil was reported on its own and when 
mixed with heroin.
Liquids
Ten seizures of liquids were reported by Estonia (6), Latvia (3), 
and Sweden (1), amounting to a total of 1.75 g. All the seizures 
took place in 2017.
In 3 cases reported by Latvia, the liquids were found in 
syringes, of which two samples also contained alpha-PHP.
In 3 cases reported by Estonia, fentanyl was also detected in 
the liquid samples.
Other physical forms
The physical form was reported as ‘other’ for 75 cases, which 
were all reported by Latvia. These amounted to a total of 
288.5 g and 0.67 ml of material seized. 47 of these samples 
also contained heroin.
No information on the physical form was reported for 
52 cases, amounting to over 136 g and 0.5 ml of material 
seized.
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Purity of carfentanil in seized samples
Information on the purity of carfentanil was provided for 
44 samples reported by Lithuania. In 25 of the cases, heroin 
was also detected and the relative concentrations of both 
substances were provided.
The purity ranged from 0.00034 to 0.13 % carfentanil (24) 
(mean: 0.043 %; median: 0.04 %). Thirty seven of the cases 
(86 %) were in the range of 0.03-0.09 % purity.
The concentration of heroin was reported for 63 samples and 
varied significantly between samples, ranging from 0.008 to 
23.9 % pure heroin.
Collected samples
Four collected samples containing carfentanil, all in powder 
form, were reported to the EMCDDA by the United Kingdom 
(2 cases), Belgium (1) and Norway (1).
Both cases reported by the United Kingdom were samples 
submitted to the drug-checking service WEDINOS. Both 
samples were submitted as ‘Fentanyl-HCL + Mannitol 15 % 
fentanyl’, but carfentanil and mannitol were analytically 
detected instead.
The sample reported by Belgium was recovered from the 
scene of an apparent suicide, where a small quantity of 
powder collected, approximately 0.005 g, was found to 
contain carfentanil.
The sample reported by Norway also relates to a serious 
adverse event, where a powder was recovered from the scene 
of a death, found in a plastic bag labelled ‘C.50’.
Biological samples
Serious adverse events with confirmed exposure to 
carfentanil from biological samples are discussed in 
section 3.4.2.
No other biological detections of carfentanil were reported to 
the EMCDDA.
(24) One very small sample was reported as ‘pure’ carfentanil, amounting to 
0.00002 g. This was considered as an outlier and, therefore, it was not included in 
the calculation.
l 
 3.3 Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the Council 
Decision)
No information concerning the involvement of organised crime 
in the manufacture and/or trafficking of the carfentanil was 
provided (25).
The United Kingdom reported that some online vendors of 
carfentanil have been identified as being run by more than 
one person; however there is little intelligence to confirm 
links to organised crime groups. Information suggests that 
carfentanil mixed with heroin was sold through travelling 
communities and networks in the North East of England, with 
this carfentanil possibly being supplied by one of these via 
online platforms/vendors.
In addition, the United Kingdom’s National Crime Agency 
reported that they identified a supplier of carfentanil who 
was using the darknet to advertise and distribute carfentanil 
across the country and also internationally.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of 
carfentanil.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of carfentanil.
l
  3.4 A first indication of the risks associated with 
the new psychoactive substance, including the health 
and social risks, and of the characteristics of users 
— Article 5.2(d) of the Council Decision
3.4.1 Health risks
Pharmacology and toxicology
Carfentanil is a highly potent μ-opioid receptor agonist that 
acts as a narcotic analgesic (Bagley et al., 1991; Frost, 2001; 
Frost et al., 1989; Janssen, 1982; Van Bever et al., 1974; 
Van Bever et al., 1976).
(25) Canada reported that they have not detected the involvement of organised 
crime groups, or that their involvement is limited. They reported that the darknet 
is often used to conduct transactions, which poses challenges in identifying the 
actors involved.
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The effects of carfentanil share some similarities with other 
opioids such as morphine and fentanyl (Janssen, 1982; 
Janssen & Van der Eycken, 1968; Van Bever et al., 1974). In 
general, the acute effects of these types of opioids include: 
euphoria, relaxation, analgesia, sedation, bradycardia, 
hypothermia, and respiratory depression (Dahan et al., 2001; 
Herz, 1993; Kieffer, 1999; Pasternak & Pan, 2013; Pattinson, 
2008; Romberg et al., 2003). They also have an abuse liability 
and dependence potential.
Similar to other fentanils, the most serious acute health 
risk from using carfentanil is likely to be rapid and severe 
respiratory depression, which in overdose could lead to 
apnoea, respiratory arrest, and death (Dahan et al., 2010; 
EMCDDA, 2017; Lindsay et al., 2016; Pattinson, 2008; 
Wax et al., 2003; White and Irvine, 1999). Factors that may 
exacerbate this risk include: the difficulty in diluting the 
substance, which can lead to a toxic dose being inadvertently 
used; the use of routes of administration that have high 
bioavailability (such as injecting, insufflation, and inhalation); 
a lack of experience with its effects and dosing; the use of 
other central nervous system depressants at the same time 
(such as other opioids, benzodiazepines, gabapentanoids, 
and alcohol); no or limited tolerance to opioids; and, using the 
substance alone (such as at home) which would make it more 
difficult for users to call for help in the case of poisoning. In 
addition, as discussed below, as carfentanil is being sold as or 
in heroin and other illicit opioids, many users will not be aware 
that they are using carfentanil.
The antidote naloxone can reverse acute poisoning, including 
respiratory depression, caused by carfentanil (Kim and 
Nelson, 2015; Tiscione and Shanks, 2016; Lindsay, et al., 
2016) (26). Recent clinical and community experience in 
treating poisonings caused by fentanils suggests that higher 
doses and additional doses (including infusions) of naloxone 
may be required to fully reverse poisoning in some cases 
(CDC, 2013; FDA, 2016; Klar et al., 2016; Sutter et al., 2017).
The chronic health risks of carfentanil may share some 
similarities to opioids such as heroin and other fentanils. 
This is likely to include dependence (Aceto et al., 1988).
3.4.2 Serious adverse events
Acute intoxications reported to the EMCDDA
In total, three acute intoxications with confirmed exposure 
to carfentanil were reported by France (2 cases) and 
(26) See also Wong et al., 2017.
Lithuania (1). The cases occurred in November 2016, 
January 2017, and May 2017 (27).
The analytical detection of other substances was not 
reported. The clinical features of the intoxications were 
generally consistent with opioid toxicity.
The intoxications were considered life-threatening in at 
least two cases; all required hospitalisation of the patients. 
Naloxone was administered to the three patients; in at least 
two cases more than one dose was given to the patient. It was 
reported that naloxone was effective in one case; in another 
case, it was reported that ‘several’ doses of naloxone were not 
effective; the response to naloxone was not reported in the 
remaining case. All the patients survived.
In one case, the patient believed he was using cocaine 
and apparently snorted a powder containing carfentanil; in 
another, the patient reportedly tried a powder they had found 
at home; while in the remaining case, carfentanil was taken as 
a substance in its own right.
Deaths reported to the EMCDDA
In total, 48 deaths with confirmed exposure to carfentanil 
were reported by Belgium (1 case), Estonia (6), Finland (1), 
Lithuania (7), Norway (1), Sweden (3), and the United 
Kingdom (29) (28). The cases occurred between November 
2016 and the first half of 2017; at least 28 (57 %) of the 
deaths occurred in the United Kingdom between February and 
May 2017.
Where known, 29 were male (85 %) and five were female 
(15 %). The males were aged between 15 and 54 years (mean 
37.8 years; median 39); the females were aged 21 to 36 years 
(mean 30.0; median 27).
A range of other substances were detected in the deaths. 
These were mostly other opioids (33 cases). Among the other 
opioids found, 6-monoacetylmorphine (6-MAM) and morphine 
(the two main active metabolites of heroin) were the most 
common detections (13 and 26 cases, respectively). Fentanyl 
and/or other fentanils were found in 22 cases (29).
Where known, most of the individuals were found dead; in 
most cases this was in a home environment. In 21 cases, 
drug paraphernalia was found at or near the scene, including 
hypodermic syringes. In some cases the deceased was still 
(27) In addition, France also reported an acute intoxication with suspected 
exposure to carfentanil. This case is not discussed further in this report.
(28) In total, 53 deaths were reported to the EMCDDA. Of these, 5 cases were 
excluded from the analysis because exposure to carfentanil had not been 
confirmed from biological samples taken from the patients.
(29) This included the detection of carfentanil, fentanyl and butyrfentanyl in 11 of 
the deaths reported by the United Kingdom.
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holding the injecting equipment, suggesting that the death 
occurred suddenly.
In the majority of cases, the cause of death has not yet been 
reported as the deaths are still under investigation. In at least 
three cases, carfentanil caused or contributed to the death.
Additional information
Additional cases of acute intoxications (30) and death 
investigations with confirmed exposure to carfentanil have 
been published in the scientific and medical literature (George 
et al., 2010; Müller et al., 2017; Seither and Reidy, 2017; 
Shanks and Behonick, 2017; Shoff et al., 2017; Sofalvi et al., 
2017; Swanson, et al., 2017; Tiscione and Shanks, 2016).
3.4.3 Characteristics of users
Similar to other fentanils, carfentanil is sold and used as a 
‘legal’ substitute for illicit opioids and prescription opioids; 
this may include for self-medication, such as the alleviation of 
pain and/or opioid withdrawal. In addition, carfentanil has also 
been sold as or in heroin in at least three Member States.
Data from law enforcement seizures and death investigations 
confirms that carfentanil is being used by high risk opioid users, 
including those who inject heroin and other illicit opioids. As 
carfentanil is being sold as or in heroin and other illicit opioids, 
most users will not be aware that they are using carfentanil. 
Other groups who may use carfentanil include those who are 
experimenting with the substance (such as psychonauts).
Evidence from Europe, the United States, and Canada shows 
that as well as being sold to users in or as heroin or other 
illicit opioids, fentanils such as carfentanil may also be sold 
as or in other illicit drugs such as cocaine, as well as used to 
make counterfeit medicines (such as opioid analgesics and 
benzodiazepines) (EMCDDA, 2017). As users will be unaware 
of this, it could increase the risk of severe and fatal poisoning 
in both opioid users and especially other user groups who 
may have no existing tolerance to opioids. Non-opioid users 
are unlikely to be aware of these risks and are unlikely to have 
access to community-based naloxone programmes, including 
take-home naloxone (EMCDDA, 2015; EMCDDA, 2016).
3.4.4 Social risks
While there is limited data for carfentanil, the social risks 
might share some similarities with other opioids such as 
heroin and other fentanils. Of particular note in this respect 
(30) These include some cases of suspected driving under the influence of drugs 
(Seither and Reidy, 2017; Tiscione and Shanks, 2016).
is that carfentanil is being used by high risk opioid users, 
including those who inject heroin and other illicit opioids.
Similar to other fentanils, accidental exposure to carfentanil 
may also pose a risk of severe poisoning. Those at risk may 
include the family and friends of users, law enforcement, 
emergency personnel, medical and forensic laboratory 
personnel, as well as those working in the postal services and 
custodial settings (CDC, 2017).
l 
 3.5 Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) 
of the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961, and the Convention on Psychotropic Substances, 1971.
On 23 May 2017, the World Health Organization informed the 
EMCDDA that carfentanil is currently not under assessment 
and has not been under assessment by the UN system.
Since then, the World Health Organization has published a 
list of substances that will be reviewed at the 39th meeting of 
the WHO Expert Committee on Drug Dependence (ECDD) 
that will be held in November 2017. Carfentanil was included 
in the list of substances that will be reviewed. At the time 
of writing this report neither a critical review nor a written 
recommendation had been published.
l  3.6 The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)
The first official EMCDDA–Europol notification of carfentanil 
dates from 12 February 2013 from the Latvian national focal 
point. The Reporting Form details the seizure of carfentanil 
in 70.139 g of light yellow powder, seized by Latvian Police in 
Riga on 8 December 2012. The substance was analytically 
confirmed by GC-MS by the State Police forensic service 
department and by GC-MS and HPLC by the Latvian Institute 
of Organic Synthesis. Sugar was also detected in the sample.
Carfentanil was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System. A profile of 
the substance was created on the European Database 
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on New Drugs (EDND). Since then, analytical details and 
other information, including a public health alert, have been 
exchanged between the EMCDDA, Europol, and the Member 
States, Turkey, and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
l 
 3.7 Information on whether or not the new 
psychoactive substance is already subject to control 
measures at national level in a Member State 
(Article 5.2(g) of the Council Decision)
Eleven Member States (Belgium, Cyprus, Czech Republic, 
Denmark, Estonia, Germany, Ireland, Latvia, Lithuania, 
Sweden, and the United Kingdom) and Norway reported that 
carfentanil is controlled under drug control legislation.
Three Member States (Austria, Hungary and Poland) reported 
that carfentanil is controlled under specific new psychoactive 
substances control legislation.
Finland reported that carfentanil is controlled under 
medicines legislation.
Thirteen Member States (Bulgaria, Croatia, France, Greece, 
Italy, Luxembourg, Malta, the Netherlands, Portugal, Romania, 
Slovakia, Slovenia and Spain) reported that carfentanil is not 
subject to control measures at the national level.
No response was received from Turkey (5).
l  3.8 Further information (Article 5.2(h) of the Council Decision)
3.8.1 The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States or 
Norway, about the chemical precursors or manufacturing 
methods used to make the carfentanil which has been 
detected within Europe.
Carfentanil can be manufactured in illicit laboratories. 
Theoretically, it could be also sourced from the diversion 
of carfentanil intended to be used for veterinary medicine.
The synthesis of carfentanil has been described in the 
literature (Van Daele et al., 1976; Fraser-Reid and Taba, 
1993; McClure et al., 1993). The synthesis of carfentanil is 
considered to be more complicated than the synthesis for 
some other fentanyl derivatives.
The synthesis of carfentanil relies on 
N-phenylethylpiperidinone (NPP) as the starting material 
(Reiff and Sollman, 1992; Van Daele et al., 1976). The 
intermediate α-aminonitrile is obtained through the Strecker 
reaction of the aminoketone with potassium cyanide and 
aniline under acidic conditions. Partial hydrolysis of this nitrile 
produces the corresponding carboxamide, which, in turn, is 
converted into the methyl carboxylate. Carfentanil is produced 
following acylation of the resulting amino ester.
A method for the synthesis of carfentanil, which utilises the 
Ugi reaction has been reported in the literature (Malaquin 
et al., 2010). The authors report that this method is original, 
straightforward, rapid and efficient and that the Ugi reaction 
can be completed without obtaining side-products. They also 
report that this synthetic method for producing carfentanil 
is achieved in only two steps and produces a high yield, in 
comparison to other previously described methods.
Other high yielding methods have been described in 
the literature, which could be utilised in the clandestine 
manfacture of carfentanil (Marton et al., 2012; Butcher 
and Hurst, 2009; Reiff and Sollman, 1992; Taber and 
Rahimizadeh, 1992).
Two potential precursors of fentanyl and other fentanils, 
N-phenyl-1-(2-phenylethyl)piperidin-4-amine (4-ANPP) as well 
as NPP (a pre-precursor), have been recently scheduled under 
the United Nations Convention against Traffic in Narcotic 
Drugs and Psychotropic Substances, 1988 (31).
The synthesis of carfentanil can be achieved using common 
laboratory equipment with commercially available glassware. 
The multi-step procedures described, require careful 
analysis and purification of the intermediates produced. The 
handling of the final product requires extreme caution to 
avoid potential absorption of the carfentanil-solution through 
the skin or the inadvertent inhalation of particles from the 
final product. Exposure of the skin and mucous membranes 
to fentanils, as well as their inhalation, poses a serious risk 
of accidental poisoning. In addition to exercising extreme 
caution, suitable personal protective equipment as well as 
sufficient stocks of naloxone as an antidote to poisoning 
following accidental exposure should be available when 
handling materials suspected to contain these substances 
(CDCP, 2013; US DEA, 2016).
(31) Table I of the United Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988.
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In summary, the synthesis of carfentanil has been described 
in the literature. There is no information on the actual 
method(s) used for the production of carfentanil that has been 
detected in Europe to date.
3.8.2 The mode and scope of the established 
or expected use of the new substance
No studies were identified that have examined the mode 
and scope of established or expected use of carfentanil. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3 Other use of the new psychoactive substance 
and the extent of such use, the risks associated with 
this use of the new psychoactive substance, including 
the health and social risks
No information was provided by the Member States or Norway 
that indicated that carfentanil had any other use apart from in 
analytical reference materials and scientific research.
From the available information, it does not appear that 
carfentanil is used in the manufacture of a medicinal product 
in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a database on the 
synthetic route of all medicinal products.
Twelve countries (Austria, Belgium, Croatia, Czech Republic, 
Finland, Germany, Greece, Latvia, the Netherlands, Slovenia, 
Spain and the United Kingdom) reported that carfentanil is not 
used to manufacture a medicinal product for human use. Four 
countries (Estonia, Hungary, Ireland and Sweden) reported 
that it was unknown if carfentanil is used to manufacture a 
medicinal product for human use.
In addition, the EMA reported that it is not known if carfentanil 
is used in the manufacture of medicinal products for human 
use and which are centrally authorised within the European 
Union.
Eleven countries (Austria, Belgium, Finland, France, Germany, 
Greece, Italy, Latvia, Poland, Slovakia and Spain) provided 
information that carfentanil is not used to manufacture a 
medicinal product for veterinary use. Six countries (Estonia, 
Ireland, the Netherlands, Portugal, Slovenia and Sweden) 
reported that it was unknown if carfentanil is used to 
manufacture a medicinal product for veterinary use.
In addition, the EMA reported that it is not known if carfentanil 
is used in the manufacture of medicinal products for 
veterinary use and which are centrally authorised within the 
European Union.
In some countries, carfentanil is used in veterinary medicine 
for the immobilization and anesthesia of large animals (De 
Vos, 1978; Lian, 2016). For example, in the United States 
it is sold under the proprietary name Wildnil® (Wildlife 
Pharmaceuticals Incorporated, N.D.).
Radiolabelled carfentanil, 11C-carfentanil, is used a positron 
emission tomography (PET) tracer in research studying the 
opioidergic system and drugs that act on that system (Frost, 
2001; Piel et al., 2014).
l  4. Information from the EMA (Article 5.3 of the Council Decision)
Sixteen countries (Austria, Belgium, Croatia, Czech Republic, 
Estonia, Finland, Germany, Greece, Hungary, Ireland, Latvia, 
the Netherlands, Slovenia, Spain, Sweden and the United 
Kingdom) reported that:
 ¡ carfentanil has not been granted a marketing authorisation 
as a medicinal product for human use;
 ¡ carfentanil is not the subject of an application for a 
marketing authorisation as a medicinal product for human 
use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to carfentanil as a human 
medicine.
Seventeen countries (Austria, Belgium, Estonia, Finland, 
France, Germany, Greece, Ireland, Italy, Latvia, the 
Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain and 
Sweden) reported that:
 ¡ carfentanil has not been granted a marketing authorisation 
as a medicinal product for veterinary use;
 ¡ carfentanil is not the subject of an application for a 
marketing authorisation as a medicinal product for 
veterinary use;
 ¡ that there had been no cases of suspended marketing 
authorisation in respect to carfentanil as a veterinary 
medicine.
14 / 19
JOINT REPORTS I Carfentanil
The EMA also reported that carfentanil:
 ¡ has not been granted a marketing authorisation as a 
medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
 ¡ is not the subject of a suspended marketing authorisation 
for neither human nor veterinary use through the 
centralised procedure.
I 5. Conclusion
Carfentanil belongs to a group of synthetic opioids known 
as the fentanils. It is closely related to fentanyl, which is 
controlled under the United Nations Single Convention on 
Narcotic Drugs, 1961. Carfentanil is likely to be a highly potent 
opioid narcotic analgesic in humans; as such, it is also likely 
to have an abuse liability and dependence potential. The 
most serious acute health risk posed by carfentanil is likely 
to be rapid and severe respiratory depression, which can be 
life-threatening. The antidote naloxone can reverse acute 
poisoning, including respiratory depression.
Carfentanil has been available in the European Union since 
at least December 2012. Since 2016, there has been an 
increase in the number of seizures reported. Typically it is 
seized as a powder, including in mixtures with heroin and 
other illicit opioids. To date, it has been detected in 8 Member 
States and Norway.
There are indications that at least some of the carfentanil 
currently available on the market is synthesised by chemical 
companies based in China. Carfentanil is sold both on the 
surface web and anonymous marketplaces on the darknet. It 
is available in wholesale amounts and in consumer amounts.
In total, 48 deaths with confirmed exposure to carfentanil 
have been reported by six Member States and Norway. Most 
of the deaths have occurred in the last six months. The 
majority of the deaths are still under investigation, however 
in at least three cases, carfentanil was the cause of death or 
contributed to the death. Many of the decedents were high 
risk opioid users, including those who inject heroin and other 
illicit opioids.
Carfentanil is sold and used as a substitute for illicit opioids 
and prescription opioids. In at least three Member States, 
carfentanil has been sold as or in heroin. Similar to other 
fentanils, serious concerns exist that the substance could be 
supplied surreptitiously to a range of drug users. Most users 
are unlikely to be aware that they are using carfentanil.
From the available information in the European Union, 
it does not appear that carfentanil has been granted a 
marketing authorisation as a medicinal product for human 
or veterinary use; is the subject of an application for a 
marketing authorisation as a medicinal product for human or 
veterinary use; or that there had been cases of suspended 
marketing authorisation in respect to carfentanil as a human 
or veterinary medicine. Furthermore, from the available 
information it does not appear that carfentanil is used in the 
manufacture of a medicinal product in the European Union. 
However, the data collection from the Member States is 
incomplete.
Carfentanil is under assessment within the United Nations 
system. It will be reviewed at the 39th meeting of the WHO 
Expert Committee on Drug Dependence (ECDD) that will be 
held in November 2017. Currently, neither a critical review nor 
a written recommendation has been published. Carfentanil is 
not subject to control measures in 13 Member States.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of carfentanil, and the 
involvement of organised crime and possible consequences 
of control measures, could be thoroughly assessed through 
a risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA.
The EMCDDA and Europol will continue to intensively monitor 
carfentanil in order to ensure that new information is provided 
to the Member States, the EMA, and the Commission via the 
information exchange of the European Union Early Warning 
System.
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